
Rozanolixizumab
4
MENTIONS
4
EPISODES
4
PODCASTS
Search complete. 4 mentions across 4 episodes found for "Rozanolixizumab".
Oct 5, 2026
Tuan H. Vu, MD - Generalized Myasthenia Gravis Across Serological Subtypes: Challenges in Diagnosis and Treatment Personalization
T
39:05Tuan H. VuGUEST
Um, this slide show the, uh, QMG scores and, uh, that mirror the effect seen with, um, MG-ADL, um, assessment.
T
39:18Tuan H. VuGUEST
Rozanolixizumab, um, was tested in the myCARING study, and, uh, it was tested versus placebo using, uh, two different doses.
T
39:27Tuan H. VuGUEST
And, and so you can see that again, um, the effect, uh, came on fairly quickly.
T
39:32Tuan H. VuGUEST
You can see that by, uh, seven days after, um, the first dose, uh, there's a, uh, improvement, um, in, in MG-ADL and also in QMG.
Tuan H. Vu, MD - Generalized Myasthenia Gravis Across Serological Subtypes: Challenges in Diagnosis and Treatment Personalization
T
39:05Tuan H. VuHOST
Um, this slide show the, uh, QMG scores and, uh, that mirror the effect seen with, um, MG-ADL, um, assessment.
T
39:18Tuan H. VuHOST
Rozanolixizumab, um, was tested in the my CARING study, and, uh, it was tested versus placebo using, uh, two different doses.
T
39:27Tuan H. VuHOST
And, and so you can see that again, um, the effect, uh, came on fairly quickly.
T
39:32Tuan H. VuHOST
You can see that by, uh, seven days after, um, the first dose, uh, there's a, uh, improvement, um, in, in MG-ADL and also in QMG.
Tuan H. Vu, MD - Generalized Myasthenia Gravis Across Serological Subtypes: Challenges in Diagnosis and Treatment Personalization
T
39:32Tuan H. VuGUEST
You can see that by, uh, seven days after, um, the first dose, uh, there's a, uh, improvement, um, in, in MG-ADL and also in QMG.
T
39:44Tuan H. VuGUEST
Uh, there was a difference between, uh, drug versus placebo, but no, uh, difference between the two doses of, uh, rozanolixizumab.
T
39:56Tuan H. VuGUEST
Um, here's a sh- a graph showing that, uh, the effect can be maintained over time, even with cyclical treatment.
T
40:03Tuan H. VuGUEST
And like, um, efgartigimod, uh, with, uh, subsequent cycles, you see the same, um, uh, benefit.
Tuan H. Vu, MD - Generalized Myasthenia Gravis Across Serological Subtypes: Challenges in Diagnosis and Treatment Personalization
T
39:05Tuan VuGUEST
Um, this slide show the, uh, QMG scores and, uh, that mirror the effect seen with, um, MG-ADL, um, assessment.
T
39:18Tuan VuGUEST
Rozanolixizumab, um, was tested in the myCARING study, and, uh, it was tested versus placebo using, uh, two different doses.
T
39:27Tuan VuGUEST
And, and so you can see that again, um, the effect, uh, came on fairly quickly.
T
39:32Tuan VuGUEST
You can see that by, uh, seven days after, um, the first dose, uh, there's a, uh, improvement, um, in, in MG-ADL and also in QMG.